Anti-CD274 (PD-L1) Antibody Pipeline

The clinical development of anti-PD-L1 agents is at the epicenter of immuno-oncology drug development. The clinical success of monoclonal antibodies targeting PD-L1 is an attractive lure, and drug development in this sphere continues at a robust pace. The Anti-CD274 (PD-L1) Antibody pipeline constitutes 80+ key companies proactively working to develop 80+ key therapies, asserts DelveInsight.Continue reading “Anti-CD274 (PD-L1) Antibody Pipeline Insights | Clinical Trials Report 2022 by DelveInsight”